Background and Scope of Evidence
Daratumumab plus lenalidomide and dexamethasone (Dara-Rd) and bortezomib plus lenalidomide and dexamethasone (VRd) both hold guideline recognition as frontline regimens for transplant-ineligible (TIE) patients with newly diagnosed multiple myeloma (NDMM). No randomized head-to-head trial has directly compared these two triplets in the TIE population, creating a significant evidentiary gap in clinical decision-making. The available evidence base comprises the pivotal phase 3 MAIA trial (Dara-Rd versus Rd), the pivotal phase 3 SWOG S0777 trial (VRd versus Rd), an anchored individual patient-level data indirect treatment comparison (ITC), cross-trial adjusted comparisons, Bayesian network meta-analyses, the CEPHEUS trial introducing quadruplet D-VRd, and patient-reported outcome analyses. This review synthesizes these sources to inform comparative benefit–risk assessment, explicitly rating the certainty of each key inference.
1. Efficacy Comparison
Pivotal Trial Outcomes
| Outcome | Dara-Rd (MAIA, 64.5-month follow-up) | Dara-Rd vs. Rd HR | VRd (SWOG S0777, 84-month follow-up) | VRd vs. Rd HR |
|---|---|---|---|---|
| Median PFS | 61.9 months | 0.55 (95% CI 0.45–0.67; P<0.0001) | 41 months | 0.742 (96% CI 0.594–0.928; P=0.003) |
| 60-month PFS rate | 52.1% vs. 29.6% (Rd) | — | Not reported at 60 months | — |
| Median OS | Not reached | 0.66 (95% CI 0.53–0.83; P=0.0003) | Not reached | 0.709 (96% CI 0.543–0.926; P=0.011) |
| 60-month OS rate | 66.6% vs. 53.6% (Rd) | — | 69% vs. 56% at 5 years (vs. Rd) | — |
| ≥Complete response | 51.1% vs. 30.1% (Rd) | P<0.0001 | 24.2% vs. 12.1% (Rd) | P<0.05 |
| ≥VGPR | 81.5% vs. 56.9% (Rd) | P<0.0001 | 74.9% vs. 53.2% (Rd) | P<0.001 |
| MRD negativity (10⁻⁵) | 32.1% vs. 11.1% (Rd) | P<0.0001 | Not assessed | — |
| Sustained MRD neg. ≥18 months | 16.8% vs. 3.3% (Rd) | P<0.0001 | Not reported | — |
Indirect treatment comparison: An anchored ITC using propensity-score–weighted individual patient-level data from MAIA and SWOG S0777 (restricted to patients ≥65 years as a proxy for TIE status) yielded a PFS hazard ratio of 0.59 (95% CI 0.39–0.90; P=0.01) favoring Dara-Rd over VRd, corresponding to a 41% relative reduction in the risk of progression or death. Sensitivity analyses (unweighted, doubly robust, hemoglobin-restricted) consistently supported this estimate. In a high-risk cytogenetic subgroup the directional trend favored Dara-Rd (HR 0.57), but this was not statistically significant owing to small sample size 1.
Network meta-analysis of 23 trials in 10,401 TIE patients reported PFS hazard ratios versus Rd of 0.57 (95% CrI 0.43–0.73) for Dara-Rd and 0.72 (95% CrI 0.56–0.90) for VRd, affirming the magnitude of PFS advantage for Dara-Rd 6. A 2025 systematic meta-analysis by Gordan et al. incorporating real-world and ITC sources reported an adjusted PFS HR of 0.56 (95% CI 0.39–0.82) favoring Dara-Rd over VRd 16.
Quadruplet context — CEPHEUS: The phase 3 CEPHEUS trial (n=395; median follow-up 58.7 months) compared daratumumab plus VRd induction with Rd maintenance (D-VRd) against VRd with Rd maintenance in TIE or transplant-deferred patients. D-VRd improved MRD negativity at 10⁻⁵ to 60.9% versus 39.4% (OR 2.37; P<0.0001), ≥CR to 81.2% versus 61.6% (P<0.0001), sustained MRD negativity ≥12 months to 48.7% versus 26.3% (P<0.0001), and produced a median PFS not reached versus 52.6 months (HR 0.57; 95% CI 0.41–0.79; P=0.0005). OS data remain immature (HR 0.85; 95% CI 0.58–1.24), with COVID-19–related deaths disproportionately affecting the longer-exposure D-VRd arm; sensitivity analyses censoring COVID-19 deaths showed a more pronounced OS trend 814.
Important subgroup note (SWOG S0777): In patients ≥65 years within SWOG S0777 (43% of the population), no statistically significant OS benefit was demonstrated for VRd (HR 0.769; P=0.168), underscoring a potential age-dependent limitation of VRd that is not observed with Dara-Rd, which demonstrated consistent PFS and OS benefit across all age strata including ≥80 years 23.
2. Safety Comparison
Grade 3/4 and Serious Adverse Events
| Adverse Event | Dara-Rd (MAIA) | VRd (SWOG S0777) |
|---|---|---|
| Any grade 3/4 TEAE | 95.9% | Not separately reported |
| Neutropenia (G3/4) | 54.1% | Reported but lower bortezomib exposure group |
| Anemia (G3/4) | 17.0% | — |
| Lymphopenia (G3/4) | 15.1% | — |
| Infection (G3/4) | 42.6% | — |
| Pneumonia (any grade) | 31.0% | — |
| Pneumonia (G3/4) | 19.5% | — |
| Grade 3/4 neurologic toxicity | 2.5% peripheral neuropathy (Dara-Rd) | 34.6% neurologic toxicity (VRd) |
| Serious AEs (any) | 78.8% | — |
| Discontinuation due to AEs | 14.6% | Bortezomib discontinuation common due to neuropathy |
Dara-Rd safety profile: The dominant grade 3/4 toxicities with Dara-Rd are hematologic — principally neutropenia (54.1%) — and infectious, with grade 3/4 infections occurring in 42.6% and pneumonia in 19.5%. Peripheral neuropathy was documented in 30.5% of patients at any grade, but grade 3/4 events were uncommon (2.5%), and this rate did not increase with extended follow-up beyond 5 years. Overall study treatment discontinuation attributable to adverse events was 14.6% — notably lower than the 23.8% discontinuation rate observed in the Rd comparator arm 2. Infusion-related reactions, characteristic of daratumumab, are typically managed with premedication and rarely require permanent discontinuation; the subcutaneous daratumumab formulation has further reduced this burden 7.
VRd safety profile: The defining toxicity concern for VRd is bortezomib-induced peripheral neuropathy. In SWOG S0777, grade 3/4 neurologic toxicity occurred in 34.6% of VRd recipients versus 11.3% with Rd (P<0.0001), representing a more than threefold increase — and this trial used intravenous bortezomib administered twice weekly, a schedule now recognized as suboptimal compared to subcutaneous or once-weekly dosing 3. The VRd-lite regimen (subcutaneous bortezomib weekly, lenalidomide 15 mg, reduced dexamethasone) was designed to mitigate this risk and demonstrated improved tolerability in a phase 2 study with an 86% ORR and ≥VGPR in 66% 13. Critically, SWOG S0777's neurologic toxicity data do not reflect contemporary VRd practice; however, bortezomib-associated neuropathy risk remains non-negligible in any schedule.
CEPHEUS quadruplet data showed that adding daratumumab to VRd did not worsen peripheral neuropathy (any-grade: 61.9% D-VRd vs. 66.2% VRd; grade 3/4: 11.2% vs. 10.8%), while treatment discontinuation due to adverse events was lower in the D-VRd arm (7.6% vs. 15.9%) 814.
3. Patient-Relevant Outcomes
Quality of life (Dara-Rd): The MAIA final analysis of patient-reported outcomes using the EORTC QLQ-C30 demonstrated that Dara-Rd recipients showed sustained improvements from baseline over 5 years in global health status, physical functioning, pain, and fatigue. At cycle 36, greater proportions of Dara-Rd patients achieved minimally important clinical improvements in global health status (OR 1.84), physical functioning (OR 1.93), fatigue (OR 2.00), and pain; median time to pain worsening was 71.5 months versus 57.5 months with Rd (HR 0.7). These benefits were consistent across elderly and frail subgroups, including patients ≥75 years and ≥80 years 9.
Quality of life (VRd): SWOG S0777 did not report formal quality-of-life assessments, representing a significant informational gap. Peripheral neuropathy at the rates observed in S0777 is well known to impair functional capacity, pain perception, and daily activities — consequences of particular importance in older, TIE patients — though no QoL instrument data are available to quantify this impact in the trial population 3.
Treatment burden and convenience: Dara-Rd involves intravenous or subcutaneous daratumumab combined with continuous oral lenalidomide and dexamethasone. Intravenous daratumumab requires weekly infusions during early cycles transitioning to monthly administration; subcutaneous formulations simplify this considerably. VRd-lite uses weekly subcutaneous bortezomib and oral agents. For frail, elderly patients with limited mobility or transportation access, the administration schedule and any required infection prophylaxis (e.g., antiviral prophylaxis with daratumumab) add logistical considerations that differ between regimens 13.
4. Benefit–Risk Synthesis
Comparative Benefit–Risk Summary by Patient Profile
| Patient Profile | Preferred Regimen | Rationale |
|---|---|---|
| Fit TIE patient (age 65–74, no neuropathy) | Dara-Rd (or D-VRd if quadruplet feasible) | Superior PFS, OS, MRD negativity; manageable toxicity |
| Elderly TIE patient (≥75 years) | Dara-Rd | Consistent PFS/OS across age subgroups; avoids bortezomib neuropathy |
| Patient with pre-existing peripheral neuropathy | Dara-Rd | Bortezomib neuropathy risk unacceptable |
| Frail patient (high comorbidity burden) | Dara-Rd or VRd-lite | Dara-Rd preferred if infection risk manageable; VRd-lite if neutropenia/pneumonia risk dominant |
| High-risk cytogenetics | D-VRd or Dara-Rd (individualize) | Attenuated benefit in both arms; proteasome inhibitor coverage in high-risk may be preferred by some guidelines |
| Patient with contraindication to daratumumab | VRd or VRd-lite | Only valid alternative |
Regimen-level interpretation: Dara-Rd offers a substantially more favorable benefit–risk profile for the majority of TIE patients. The 41% relative PFS risk reduction versus VRd (indirect comparison), combined with a 34% OS risk reduction versus Rd, superior MRD-negativity rates (32.1% vs. ~11%), higher CR rates (51.1% vs. ~24% with VRd), and meaningful QoL gains are counterbalanced by higher neutropenia and pneumonia rates. Importantly, treatment discontinuation due to adverse events was 14.6% with Dara-Rd in MAIA, suggesting that long-term treatment was feasible in a substantial proportion of patients. Peripheral neuropathy — the clinically most disabling regimen-specific toxicity of VRd — is uncommon (grade 3/4: 2.5%) with Dara-Rd 1210.
VRd remains a valid option in specific circumstances: patients with contraindications to daratumumab, patients for whom intensive infection prophylaxis is not feasible, or those in whom bortezomib's coverage of high-risk cytogenetic disease is considered mechanistically important. When VRd is used, subcutaneous and/or weekly dosing schedules (VRd-lite) are strongly preferred to reduce neuropathy. The NCCN 2024–2025 guidelines designate Dara-Rd as a Category 1, preferred frontline option, while VRd-lite is rated "useful in certain circumstances" with Category 2A evidence 13.
5. Certainty of Evidence and Limitations
| Key Outcome | Comparison | Certainty Rating | Rationale |
|---|---|---|---|
| PFS benefit of Dara-Rd vs. Rd | Direct (MAIA) | High | Large RCT (n=737), mature 64.5-month follow-up, consistent subgroup results |
| OS benefit of Dara-Rd vs. Rd | Direct (MAIA) | High | Statistically significant at 64.5 months; 60-month rates 66.6% vs. 53.6% |
| PFS benefit of VRd vs. Rd | Direct (S0777) | High | Large RCT (n=460), 84-month follow-up; caveat: mixed TIE/TE population |
| PFS advantage of Dara-Rd vs. VRd | Indirect ITC | Moderate | ITC uses individual patient-level data with propensity weighting, but residual confounding, different maintenance strategies, and age-restriction (≥65) limit certainty |
| OS advantage of Dara-Rd vs. VRd | Indirect | Low–Moderate | No direct comparison; OS HR from respective trials comparable in magnitude but different populations |
| MRD negativity with Dara-Rd | Direct (MAIA) | High | Prespecified endpoint; sustained negativity rates significantly superior |
| MRD negativity with VRd | Not assessed | Insufficient | SWOG S0777 did not evaluate MRD |
| Safety of Dara-Rd | Direct (MAIA) | High | Comprehensive long-term data; no new signals at 5-year follow-up |
| Safety of VRd (modern schedules) | Limited | Moderate | S0777 used IV twice-weekly bortezomib; not representative of subcutaneous/weekly practice |
| QoL with Dara-Rd | Post hoc MAIA | Moderate | Post hoc analysis with declining compliance in later cycles; consistent across domains and subgroups |
| QoL with VRd | Not reported | Insufficient | No formal QoL data from S0777 |
Major limitations:
-
Absence of a head-to-head RCT: No prospective trial has directly randomized TIE NDMM patients to Dara-Rd versus VRd. All comparative inferences rely on indirect evidence with potential residual confounding; the prospective SWOG S2209 trial is expected to provide definitive comparative data.
-
Population heterogeneity: MAIA enrolled exclusively TIE patients (median age 73 years; 99% ≥65 years; 44% ≥75 years), while SWOG S0777 enrolled a mixed population (median age 63 years; 43% ≥65 years; not all truly TIE). The ITC restricted to ≥65 years excluded 43% of S0777 participants, limiting generalizability to younger TIE patients.
-
Treatment design differences: MAIA used continuous Dara-Rd until progression; SWOG S0777 used 8 cycles of VRd induction followed by Rd maintenance. These structural differences confound long-term comparisons of response deepening and duration.
-
Bortezomib formulation: Twice-weekly intravenous bortezomib in S0777 produced neuropathy rates (G3/4: 34.6%) not representative of modern subcutaneous weekly schedules or VRd-lite. Contemporary VRd toxicity is lower, though the relative advantage of Dara-Rd with respect to neuropathy is preserved regardless of bortezomib schedule.
-
CEPHEUS frailty exclusion: The CEPHEUS trial excluded frail patients (frailty index ≥2), limiting the applicability of quadruplet D-VRd evidence to the broader, often frail TIE population 814.
Integrated Benefit–Risk Conclusion
For the majority of TIE patients with NDMM, Dara-Rd provides a compelling benefit–risk profile that currently positions it as the preferred frontline triplet regimen. The evidence demonstrates superior PFS (median 61.9 vs. 41 months with VRd from respective trials; indirect HR 0.59 favoring Dara-Rd), a meaningful OS benefit, substantially higher MRD-negativity rates (32.1% at 10⁻⁵), and deeper responses (≥CR: 51.1%), accompanied by sustained QoL improvements — all achieved with notably low rates of peripheral neuropathy (grade 3/4: 2.5%) and acceptable treatment discontinuation (14.6%) 1269. This benefit profile holds consistently across elderly subgroups, including patients ≥80 years.
VRd and VRd-lite retain an important clinical role for patients with contraindications to daratumumab or for whom the infection burden and neutropenia associated with Dara-Rd are particularly high-risk. Quadruplet D-VRd offers the deepest responses and longest PFS of any currently evaluated strategy for fit TIE or transplant-deferred patients, though OS data are immature and frail patients require individualized assessment 814. The certainty of comparative evidence between Dara-Rd and VRd is moderate, driven primarily by the absence of a direct head-to-head RCT, and clinicians should incorporate individual patient characteristics, comorbidities, neuropathy risk, logistical feasibility, and patient preferences when making frontline treatment decisions.